The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H- benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site

Molecular Pharmacology

Volumn 78, Issue 4, 2010, Pages 648-657

  Jacobson, Marlene A ^a   Kreatsoulas, Constantine ^a   Pascarella, Danette M ^a   O'Brien, Julie A ^a   Sur, Cyrille ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1' (2 METHYLBENZYL) 1,4' BIPIPERIDIN 4 YL] 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 4 N BUTYL 1 [4 (2 METHYLPHENYL) 4 OXO 1 BUTYL]PIPERIDINE HYDROGEN CHLORIDE; AC 42; ACETYLCHOLINE; CLOZAPINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; NORCLOZAPINE; UNCLASSIFIED DRUG; XANOMELINE; 1-(1'-(2-METHYLBENZYL)-1,4'-BIPIPERIDIN-4-YL)-1H-BENZO(D)IMIDAZOL-2-(3H)-ONE; 4-N-BUTYL-1-(4-(2-METHYLPHENYL)-4-OXO-1-BUTYL)-PIPERIDINE HYDROGEN CHLORIDE; BENZIMIDAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE;

ALLOSTERISM; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CALCIUM MOBILIZATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG STRUCTURE; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; AGONISTS; CHEMISTRY; COMPARATIVE STUDY; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ACETYLCHOLINE; ALLOSTERIC REGULATION; ALLOSTERIC SITE; AMINO ACID SEQUENCE; BENZIMIDAZOLES; BINDING SITES; HUMANS; MOLECULAR SEQUENCE DATA; PIPERIDINES; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, MUSCARINIC M1;

EID: 77957233070     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065771     Document Type: Article

References (35)

1. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
2. Birdsall NJ, Lazareno S, Popham A, and Saldanha J (2001) Multiple allosteric sites on muscarinic receptors. Life Sci 68:2517-2524. (Pubitemid 32455690)
3. Birdsall NJ and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5:523-543.
4. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473.
5. Bymaster FP, McKinzie DL, Felder CC, and Wess J (2003) Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28:437-442.
6. Caccamo A, Fisher A, and LaFerla FM (2009) M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 6:112-117.
7. De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, and Mohr K (2010) Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 30:463-549.
8. Fredriksson R, Lagerström MC, Lundin LG, and Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256-1272.
9. Halgren TA (1999) MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem 20:720-729.
10. Hulme EC, Lu ZL, and Bee MS (2003) Scanning mutagenesis studies of the M1 muscarinic acetylcholine receptor. Receptors Channels 9:215-228.
11. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, and Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins 55: 351-367.
12. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, et al. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422-10433.
13. Langmead CJ and Christopoulos A (2006) Allosteric agonists of TM7 receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 27:475-481.
14. Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, Wood MD, and Herdon HJ (2006) Probing the molecular mechanism of interaction between 4-nbutyl- 1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 69:236-246.
15. Langmead CJ, Watson J, and Reavill C (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117:232-243.
16. Lazareno S, Gharagozloo P, Kuonen D, Popham A, and Birdsall NJ (1998) Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol 53: 573-589.
17. Lebon G, Langmead CJ, Tehan BG, and Hulme EC (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol Pharmacol 75:331-341.
18. Lu ZL and Hulme EC (1999) The functional topography of transmembrane 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis. J Biol Chem 274:7309-7315.
19. Lu ZL, Saldanha JW, and Hulme EC (2001) Transmembrane domains 4 and 7 of the M1 muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch. J Biol Chem 276:34098-34104.
20. Ma L, Seager MA, Seager M, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, et al. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 106:15950-15955.
21. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, et al. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75:577-588.
22. Murakami M and Kouyama T (2008) Crystal structure of squid rhodopsin. Nature 453:363-367.
23. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
24. Matsui H, Lazareno S, and Birdsall NJ (1995) Probing of the location of the allosteric site on the m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
25. Page KM, Curtis CA, Jones PG, and Hulme EC (1995) The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. Eur J Pharmacol 289:429-437.
26. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289:739-745.
27. Peng JY, Vaidehi N, Hall SE, and Goddard WA 3rd (2006) The predicted 3D structures of the human M1 muscarinic acetylcholine receptor with agonist or antagonist bound. Chem Med Chem 1:878-890.
28. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, and Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039.
29. Sherman W, Beard HS, and Farid R (2006) Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 67:83-84.
30. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, and Brann MR (2002) Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 61:1297-1302.
31. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, and Burstein ES (2006) Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 70:1974-1983. (Pubitemid 44771913)
32. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, and Conn PJ (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptors, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679. (Pubitemid 37444798)
33. Voigtländer U, Jöhren K, Mohr M, Raasch A, Tränkle C, Buller S, Ellis J, Höltje HD, and Mohr K (2003) Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol 64:21-31.
34. Ward SD, Curtis CA, and Hulme EC (1999) Alanine-scanning mutagenesis of transmembrane domain 6 of the M1 muscarinic acetylcholine receptor suggests that Tyr381 plays a key role in receptor function. Mol Pharmacol 56:1031-1041.
35. Wess J, Duttaroy A, Zhang W, Gomeza J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, et al. (2003) M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 9:279-290.